Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more
here
.
About Us
About hVIVO
Leadership Team
Our Companies
Key Stats
History
Services
Challenge Trials
RSV
Influenza
COVID-19
HRV
Malaria
Asthma & COPD
Laboratory Services
Assay Development
Field Trial Bio-logistics
Cell Based Assays
Molecular Services
Compound Efficacy & VRM
Biomarker Analysis
Phase II-III Clinical Trials
Vaccine Phase II-III Trials
Articles & Research
News & Media
Regulatory News
Media Coverage
Media Press Kit
Video Library
Events
Investors
New
Investors
Regulatory News & Email Alerts
Results Centre
Share Price Information
Events & Presentations
Environmental, Social & Governance
AIM Rule 26
Advisors
Documents
Corporate Governance
Volunteers
Careers
Contact Us
Contact Us
Articles & Research
from hVIVO
Article Types Filter
Article Types Filter
Blog
Article
Presentation
Scientific Paper
Factsheet
Case Study
Article Count
1 - 10 of 36 posts
Scientific Paper
17 Aug 2022
Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial
View Link
Case Study
16 Aug 2022
RSV Human Challenge Study as a tool for a break-through designation
An international biotech company, headquartered in the EU approached hVIVO to explore the possibility of performing a RSV Phase IIa challenge study. The investigational product was a novel recombinant modified...
Read more
Blog
08 Jun 2022
Infectious Diseases Blog – ‘The Pathogenda’ Part 5
In one of the most important discoveries in medicine this year, Epstein-Barr virus (EBV) has been collared as the link/early causal role in multiple sclerosis. Finding the virus underpinning multiple...
Read more
Blog
19 May 2022
Infectious Diseases Blog – ‘The Pathogenda’ Part 4
So we know, or at least it is being widely reported, that depression and anxiety indices are raised worldwide, and most especially in High Income Countries (HIC). Whilst this is...
Read more
Scientific Paper
12 May 2022
Human infection studies: Key considerations for challenge agent development and production
View Link
Blog
06 May 2022
Infectious Diseases Blog – ‘The Pathogenda’ Part 3
Spring continues to bring its oft’ mixed blessings of sunshine and showers, as expressed over four hundred years ago in this short poem by Thomas Tusser in ‘A Hundred Good...
Read more
Blog
13 Apr 2022
Infectious Diseases Blog – ‘The Pathogenda’ Part 2
Hello and welcome all to a sunny spring but one somewhat diminished in its capacity for ‘joy in the morning’ by a vicious uptick in BA.2 infections globally, with the...
Read more
Scientific Paper
31 Mar 2022
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
View Link
Blog
30 Mar 2022
Infectious Diseases Blog – ‘The Pathogenda’ Part 1
View Link
Scientific Paper
17 Feb 2022
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge
View Link
Article Pagination
1
2
3
4
Articles Per Page
Articles Per Page
8
10
16
24
32
angle-down
meetup
chevron-down